Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: A nested case-control analysis

Liver International

Volumn 32, Issue 8, 2012, Pages 1233-1241

  Wan, Shaogui ^a   Hann, Hie Won ^a,b   Myers, Ronald E ^a   Fu, Xiaoying ^a   Hann, Richard S ^a   Kim, Su H ^a   Tang, Heng ^a   Xing, Jinliang ^c   Yang, Hushan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cirrhosis; HBV; Telomere length

Indexed keywords

DNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RISK; STATISTICAL SIGNIFICANCE; TELOMERE HOMEOSTASIS;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA; FEMALE; GENETIC MARKERS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TELOMERE;

EID: 84865166086     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02801.x     Document Type: Article

References (40)

1. Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998; 74: 193-202.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49(Suppl. 5): S28-34.
4. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
5. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-73.
6. Blackburn EH. Telomeres. Trends Biochem Sci 1991; 16: 378-81.
7. Klapper W, Parwaresch R, Krupp G. Telomere biology in human aging and aging syndromes. Mech Ageing Dev 2001; 122: 695-712.
8. Houben JM, Moonen HJ, Van Schooten FJ, Hageman GJ. Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med 2008; 44: 235-46.
9. Gilley D, Tanaka H, Herbert BS. Telomere dysfunction in aging and cancer. Int J Biochem Cell Biol 2005; 37: 1000-13.
10. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 2004; 41: 491-7.
11. Butt HZ, Atturu G, London NJ, Sayers RD, Bown MJ. Telomere length dynamics in vascular disease: a review. Eur J Vasc Endovasc Surg 2010; 40: 17-26.
12. Kitada T, Seki S, Kawakita N, Kuroki T, Monna T. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995; 211: 33-9.
13. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-42.
14. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, Depinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-8.
15. Saliques S, Zeller M, Lorin J, et al. Telomere length and cardiovascular disease. Arch Cardiovasc Dis 2010; 103: 454-9.
16. Kim S, Parks CG, Deroo LA, et al. Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev 2009; 18: 816-20.
17. Testa R, Olivieri F, Sirolla C, et al. Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus. Diabet Med 2011; 28: 1388-94.
18. Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta 2009; 1792: 317-23.
19. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011; 20: 1238-50.
20. Yang H, Lippman SM, Huang M, et al. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer 2008; 44: 1603-11.
21. Mitchell DG, Lovett KE, Hann HWet al.Cirrhosis: multiobserver analysis of hepatic MR imaging findings in a heterogeneous population. Journal of Magnetic Resonance Imaging: JMRI 1993; 3: 313-21.
22. Ito K, Mitchell DG, Hann HW, Outwater EK, Kim Y. Compensated cirrhosis due to viral hepatitis: using MR imaging to predict clinical progression. AJR Am J Roentgenol 1997; 169: 801-5.
23. Ito K, Mitchell DG, Hann HW, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207: 729-35.
24. Kudo M, Zheng RQ, Kim SR, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 2008; 51(Suppl. 1): 17-26.
25. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
26. Schmid P, Tong M, Conrad A, Mchutchison J, Blatt LM. Analysis of the viability of freezer stored serum samples for hepatitis C virus RNA analysis by the SUPERQUANT method: results of a 16 year retrospective study. J Virol Methods 1999; 82: 201-6.
27. Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009; 49(Suppl. 5): S22-7.
28. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49(Suppl. 5): S4-12.
29. Liu J, Yang Y, Zhang H, et al. Longer leukocyte telomere length predicts increased risk of hepatitis b virus-related hepatocellular carcinoma: a case-control analysis. Cancer 2011; 117: 4247-56.
30. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007; 45: 968-76.
31. Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011; 53: 1608-17.
32. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004; 40: 80-6.
33. Zhu H, Wang X, Gutin B, et al. Leukocyte telomere length in healthy Caucasian and African-American adolescents: relationships with race, sex, adiposity, adipokines, and physical activity. J Pediatr 2011; 158: 215-20.
34. Eisenberg DT, Salpea KD, Kuzawa CW, Hayes MG, Humphries SE. Substantial variation in qPCR measured mean blood telomere lengths in young men from eleven European countries. Am J Hum Biol 2011; 23: 228-31.
35. Roux AV, Ranjit N, Jenny NS, et al. Race/ethnicity and telomere length in the multi-ethnic study of atherosclerosis. Aging Cell 2009; 8: 251-7.
36. Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 2003; 22: 4003-13.
37. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 2004; 40: 276-83.
38. Lee JE, Oh BK, Choi J, Park YN. Telomeric 3′ overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma. Int J Cancer 2008; 123: 264-72.
39. Zhang C, Guo X, Jiang G, et al. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 2008; 123: 998-1004.
40. Saini N, Srinivasan R, Chawla Yet al. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int 2009; 29: 1162-70.